NCT00316758View on ClinicalTrials.gov

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

PHASE2CompletedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

GK Activator (2)

Escalating doses bid

DRUG

Metformin

As prescribed, in patients who were in study BM18249

Trial Locations (58)

1083

Budapest

1233

Sofia

1606

Sofia

2050

Camperdown

3081

Heidelberg

5800

Pleven

6000

Kecskemét

6400

Dimitrovgrad

7002

Rousse

9024

Győr

10000

Zagreb

10115

Berlin

11650

Mexico City

13901

Binghamton

14050

Mexico City

14610

Mexico City

15009

Beaver

20249

Hamburg

27103

Winston-Salem

28304

Fayetteville

28625

Statesville

29464

Mt. Pleasant

30308

Atlanta

31238

Chihuahua City

33021

Hollywood

34070

Durango

34741

Kissimmee

35385

Giessen

36142

Tann

38119

Memphis

45246

Springdale

45355

Essen

59701

Butte

62270

Cuernavaca

67005

Arkansas City

69245

Bammental

73112

Oklahoma City

90057

Los Angeles

90402

Nuremberg

91307

West Hills

91910

Chula Vista

91911

Chula Vista

91978

Spring Valley

94550

Künzing

97504

Medford

98003

Federal Way

98055

Renton

V5Z 1M9

Vancouver

NGA 4V2

London

H1T 2M4

Montreal

02826

Görlitz

01015

Guatemala City

06700

Mexico City

15-276

Bialystok

80-757

Gdansk

66-400

Gorzów

31-121

Krakow

50-088

Wroclaw

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00316758 - A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes. | Biotech Hunter | Biotech Hunter